

1 **Sitagliptin decreases visceral fat and blood glucoses in women with polycystic ovarian**
2 **syndrome**

3 Jessica K. Devin MD MSCI¹, Hui Nian PhD², Jorge E. Celedonio MD³, Patricia Wright RN³,
4 Nancy J. Brown MD³

5 ¹Division of Diabetes, Endocrinology, and Metabolism, ²Department of Biostatistics, ³Division of
6 Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN

7 **Short Title:** Sitagliptin improves VAT and blood glucoses in PCOS

8 **Key words:** dipeptidyl peptidase-4, growth hormone, insulin like growth factor-1, polycystic
9 ovarian syndrome, visceral adiposity

10 **Corresponding Author:** Jessica Devin, MD MSCI, Phone 615-498-8290,
11 Jessica.devin@vumc.org

12 **Reprint Requests:** Nancy J. Brown, MD, Phone 615-343-8701, Nancy.j.brown@vumc.org

13 **Sources of Funding:** This research was supported by Vanderbilt Clinical and Translational
14 Science Awards (CTSA) grant UL1 TR000445-06 from the NIH National Center for Advancing
15 Translational Sciences. The Vanderbilt Hormone Assay and Analytical Services Core is
16 supported by NIH grants DK059637 and DK020593. JKD was supported by K23HL11962
17 NHLBI/NIH and NJB by R01HL125426 from NHLBI/NIH.

18 **Disclosures:** The authors have nothing to disclose.

19 **Clinical Trial Registration:** This study was registered at www.clinicaltrials.gov as
20 NCT02122380 prior to enrollment of the first participant.

21 **Context:** Women with polycystic ovarian syndrome (PCOS) have decreased growth hormone
22 (GH), which can increase visceral adiposity (VAT) and impair vascular function. GH releasing
23 hormone, a dipeptidyl peptidase-4 (DPP4) substrate, stimulates GH secretion.

24 **Objective:** We tested the hypothesis that DPP4 inhibition increases GH and improves glucose
25 levels and vascular function in women with PCOS.

26 **Methods:** Eighteen women with PCOS participated in a double-blinded, cross-over study. They
27 received sitagliptin 100 mg vs. placebo daily for one month separated by an eight-week
28 washout. During each treatment, women underwent a 75-gram oral glucose tolerance test
29 (OGTT), assessment of vascular function and body composition. Overnight GH secretion was
30 assessed via venous sampling every 10 minutes for 12 hours and analyzed using an automated
31 deconvolution algorithm.

32 **Results:** During OGTT, sitagliptin increased GLP-1 ($p<0.001$), early insulin secretion (from
33 mean insulinogenic index 1.9 ± 1.2 (SD) to 3.2 ± 3.1 ; $p=0.02$) and decreased peak glucose (mean
34 -17.2 mg/dL [95% CI $-27.7, -6.6$]; $p<0.01$). At one month, sitagliptin decreased VAT (from
35 1141.9 ± 700.7 to 1055.1 ± 710.1 g; $p=0.02$) but did not affect vascular function. Sitagliptin
36 increased GH half-life (from 13.9 ± 3.6 to 17.0 ± 6.8 min, $N=16$; $p=0.04$) and interpulse interval
37 (from 53.2 ± 20.0 to 77.3 ± 38.2 min, $N=16$; $p<0.05$) but did not increase mean overnight GH
38 ($p=0.92$ vs. placebo).

39 **Conclusions:** Sitagliptin decreased the maximal glucose response to OGTT and VAT.
40 Sitagliptin did not increase overnight GH but increased GH half-life and the interpulse interval.

41

42 **Precis:** Sitagliptin improved body composition and blood glucoses following oral glucose load in
43 women with PCOS. Sitagliptin potentiated GH half-life but did not increase overnight GH levels.

44 **Introduction**

45 Growth hormone (GH) is secreted in a pulsatile fashion from the pituitary gland and exerts its
46 effects either directly, via activation of the GH receptor, or indirectly, through hepatic insulin-like
47 growth factor-1 (IGF-1). In adults, GH has important effects on the vasculature and body
48 composition. GH increases endothelium-dependent vasodilator function and reduces
49 inflammation.(1-3) We have previously shown that patients with low GH have impaired conduit
50 artery vasodilator function along with decreased tissue-type plasminogen activator (tPA) activity
51 and a defective fibrinolytic response to venous occlusion.(4) Others have corroborated these
52 findings and further demonstrated that these vascular indices improve with GH replacement
53 therapy.(3,5) GH also has anabolic and lipolytic effects. Conversely, GH secretion is reduced
54 in obesity and particularly in individuals with visceral adiposity. Women with increased visceral
55 adipose tissue (VAT) demonstrate a four-fold reduction in mean GH levels as compared to
56 those without.(6) Normalization of GH secretion in patients with diminished GH affords one
57 potential mechanism to address simultaneously both VAT and cardiovascular risk.
58 Unfortunately, therapy with recombinant GH does not restore pulsatile secretion, is not subject
59 to physiologic negative feedback by IGF-1, and is limited by hyperglycemia.(7)

60

61 We propose that an alternative strategy to enhance endogenous GH secretion in humans is to
62 inhibit the degradation of endogenous GH releasing hormone (GHRH) by the dipeptidyl
63 peptidase-4 (DPP4) enzyme. GHRH is the primary stimulus for pituitary GH secretion and
64 determines GH pulsatility. Endogenous GHRH has a half-life of six minutes as it is degraded
65 and inactivated by DPP4.(8,9) Sitagliptin was the first oral DPP4 inhibitor approved by the US
66 Food and Drug Administration for the management of hyperglycemia in patients with type 2
67 diabetes mellitus. Sitagliptin improves post-prandial hyperglycemia in a glucose-dependent

68 manner by decreasing the degradation of the incretin hormone, glucagon-like peptide-1 (GLP-
69 1), and can therefore be safely given to patients without diabetes mellitus.(10) We recently
70 found that acute DPP4 inhibition with sitagliptin enhances stimulated GH secretion and free
71 IGF-1 levels in healthy, lean women. Moreover, while vasodilation and tPA activity levels
72 increased in both men and women during stimulated GH secretion, women demonstrated an
73 enhanced vascular response to increased GH.(11) The effect of chronic DPP4 inhibition on
74 pulsatile GH secretion in individuals with low GH levels has not been studied.

75

76 Women with polycystic ovarian syndrome (PCOS) have decreased GH secretion characterized
77 by an impaired GH response to stimuli and a greater than 50% reduction in 24-hour mean GH
78 levels.(12-14) Approximately ten percent of reproductive-aged women in the United States are
79 affected by PCOS at an estimated annual cost of over four billion dollars.(15) These women are
80 often overweight and are at increased risk for future cardiovascular disease and diabetes
81 mellitus. There are currently no approved medical therapies for women with PCOS;
82 management options include weight loss or medications aimed at controlling symptoms of
83 hirsutism or oligomenorrhea, or treatment of insulin resistance.(16,17) In this study, we tested
84 the hypothesis that one month of DPP4 inhibition with sitagliptin would enhance overnight
85 pulsatile GH secretion in overweight women with PCOS and improve glucose metabolism.
86 Given the effects of GH on the vasculature, we also hypothesized that an increase in GH would
87 enhance endothelial function and fibrinolysis.

88

89 **Materials and Methods**

90 Study Protocol

91 Eighteen women (BMI ≥ 25 kg/m²) with PCOS, 18 through 45 years of age completed a double-
92 blind, randomized, placebo-controlled, crossover study. (See **Table 1** for subject characteristics
93 and **Figure 1** for participant flow diagram.) The study adhered to the principles of the
94 Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of
95 Human Subjects and was approved by the Vanderbilt University Medical Center Institutional
96 Review Board. All subjects provided written informed consent prior to initiation of study
97 procedures. A diagnosis of PCOS was confirmed when women met two out of the three 2003
98 Rotterdam criteria: oligomenorrhea (menstrual cycles occurring at intervals >35 days, or only 4-
99 9 cycles per year) or secondary amenorrhea (no cycle in 3 months if previously regular or no
100 cycle in 9 months if previous oligomenorrheic); clinical and/or laboratory evidence of
101 hyperandrogenism; previous evidence of polycystic ovaries on ultrasound examination. Other
102 common causes of hyperandrogenemia and oligomenorrhea, including hyperprolactinemia, late-
103 onset 21-hydroxylase deficiency, and inadequately treated hypothyroidism were excluded at the
104 time of screening visit.(18) Patients with a history of chronic illness, including diabetes mellitus,
105 hypertension, cardiovascular disease, and chronic renal or hepatic insufficiency as well as a
106 history of weight loss surgery or ongoing night-shift work were excluded. Women were required
107 to discontinue oral contraceptives for eight weeks and spironolactone for thirty days prior to
108 study enrollment, if applicable. One woman took a stable dose of metformin throughout the
109 study; other drugs known to alter glucose or insulin metabolism were not permitted. Pregnancy
110 was excluded in all women of child-bearing age by serum pregnancy testing prior to study drug
111 initiation and again prior to performing dual-energy x-ray absorptiometry (DEXA).

112

113 Women underwent two one-month treatment periods separated by wash-out period of at least
114 eight weeks (**Figure 2**). Subjects were assigned to treatment order (double-blinded sitagliptin
115 100 mg p.o. qd or matching placebo) using a block randomization algorithm. On each outpatient

116 and inpatient study day, subjects reported to the Vanderbilt Clinical Research Center (CRC) in
117 the morning after an overnight fast. After approximately two weeks of study drug, subjects
118 underwent an extended OGTT. One hour after oral study drug (sitagliptin vs. placebo) a
119 peripheral intravenous line was placed in the antecubital fossa of the non-dominant arm.
120 Baseline venous samples and vital signs were obtained at least 60 minutes following study
121 drug. Oral glucola (75 grams) was then ingested within 10 minutes, and samples were obtained
122 over the following 270 minutes. Women were then discharged and continued daily study drug
123 at home for an additional two weeks.

124

125 On the last day of study drug, women again reported to the CRC following an overnight fast.
126 One hour after the last dose of oral study drug, vital signs, weight, and fasting venous samples
127 were obtained via peripheral stick in the non-dominant arm. Women then underwent
128 assessment of endothelium-dependent and independent vasodilation in the dominant arm (see
129 “conduit artery vascular function” below). In the afternoon, total and regional body composition
130 was determined by a certified densitometrist using dual-energy X-ray absorptiometry (Lunar
131 iDXA; GE Health Care, Madison, WI) with enCore software (version 13.6). Women also
132 completed the previously validated polycystic ovarian syndrome questionnaire (PCOSQ).(19-21)
133 In the evening, women underwent placement of an indwelling venous catheter and venous
134 blood was sampled for GH every ten minutes from 8 PM until 8 AM. Meal content and
135 composition were standardized across all subjects, and intake of the standardized meals was
136 matched within each woman across study arms. Snacking and exercise were not permitted in
137 the CRC. Only water intake was permitted during GH sampling.

138

139 Conduit Artery Vascular Function

140 Endothelium-dependent vasodilation was evaluated in a temperature-controlled room in the
141 fasting state after 15 minutes of rest in the supine position. Participants were asked to refrain
142 from exercise, alcohol, caffeine, and anti-inflammatory medications for 24 hours preceding each
143 measurement. Studies could not be coordinated with the phase of the menstrual cycle due to
144 the infrequency or absence of cycles in the majority of our volunteers. Vascular images were
145 obtained by a single ultrasound-trained technician using an L12-3 broadband linear array
146 transducer attached to a high-resolution ultrasound machine (EPIQ7C; Phillips, Bothwell, WA).
147 A longitudinal image (parallel to the artery) was acquired just proximal to the antecubital fossa of
148 the dominant arm with the transducer positioned to optimize images of the near and far wall
149 interfaces. Depth and gain settings were optimized to identify the interface between the lumen
150 and blood vessel wall. Anatomical landmarks were documented while positioning the probe, to
151 facilitate repositioning during repeated studies. A simultaneous electrocardiogram signal was
152 recorded throughout the imaging. To assess endothelium-dependent vasodilation, brachial
153 artery diameter was measured under basal conditions and during reactive hyperemia. Reactive
154 hyperemia was achieved by inflating a pneumatic cuff on the upper arm to 200 mmHg for five
155 minutes. The cuff was deflated and images of the artery were obtained continuously across the
156 cardiac cycle for 180 seconds after cuff release. Baseline velocity time integral (VTI) was
157 determined prior to cuff occlusion and hyperemic VTI was determined for ten beats post-cuff
158 release via pulse-wave spectral Doppler recordings. Following a 15-minute rest period, the
159 brachial artery was imaged again to re-establish basal conditions. Endothelium-independent
160 vasodilation was then determined by administering 0.4 mg nitroglycerin sublingually. The
161 brachial artery was imaged three minutes later for two minutes. Nitroglycerin was only
162 administered if systolic blood pressure was at least 110 mm Hg, pulse at least 60 bpm, and with
163 the participant's consent (N=3 participants).

164

165 Acquisition and analysis of the DICOM-stored images was performed using software (Brachial
166 analyzer 5.0) designed for this purpose by Medical Imaging Applications LLC (Iowa City, Iowa).
167 The vessel wall-lumen interface was determined by derivative based edge detection following
168 identification of the region of interest by the blinded investigator (JKD). The selected region of
169 interest was consistent across study days for the same subject. The maximum diameter post-
170 hyperemia was obtained using previously described custom design software which
171 automatically calculates the time to peak and peak dilation.(22) This software implements the
172 method validated by Green et al. which uses a smoothing algorithm to correct for changes in the
173 brachial artery diameter during the cardiac cycle.(23) The percent change in diameter, following
174 reactive hyperemia and nitroglycerin, was then calculated as percent vasodilation= $[(\text{peak}$
175 $\text{diameter}-\text{baseline diameter})/\text{baseline diameter}]*100$. The reactive hyperemia-induced increase
176 in VTI relative to baseline was calculated as a ratio= $\text{hyperemia VTI}/\text{baseline VTI}$.

177

178 Laboratory Analyses

179 All samples were obtained after the first 3 mL of blood were discarded. Blood samples were
180 collected on ice, centrifuged immediately and plasma stored at -80°C in pre-specified aliquots
181 until time of assay. All samples obtained from each subject during sitagliptin and placebo
182 treatment were simultaneously analyzed with internal controls. DPP4 activity was assayed by
183 incubating 20 μl sample in 80 μl assay buffer (0.1 M Tris at a pH of 8.0; Bachem, Torrance, CA)
184 for 30 minutes at 37°C with colorimetric substrate [2 mM L-glycyl-L-prolyl p-nitroanilide
185 hydrochloride (Sigma Aldrich, St. Louis, MO)] for a total reaction volume of 200 μL , as
186 previously described.(24) DPP4 antigen concentration was determined by enzyme-linked
187 immunoassay (ELISA) (eBioscience; San Diego, CA). The enzyme activity was assessed by
188 measuring the increase in specific absorbance at 405 nm at 0, 15, and 30 minutes and was

189 expressed as nmol/mL/min. Percent DPP4 inhibition was determined by the equation: $[1 - (\text{DPP4}$
190 $\text{activity during sitagliptin} / \text{DPP4 activity during placebo})] * 100$. GH levels were determined by
191 two-site immunoassay (Beckman Access Ultrasensitive human GH assay, Beckman Coulter,
192 Inc.) performed on the Dxl automated immunoassay system (Beckman Instruments; Chaska
193 MN) and calibrated against NIBSC WHO IS 98/574 with an analytic measurement range of
194 0.002 to 35 ng/mL. The first five subjects were analyzed at Brigham Research Assay Core
195 (Boston, MA); the intra-assay CV was 1.48-11.26% and the inter-assay CV was 1.96-14.4%.
196 The remaining subjects were analyzed at the Mayo Immunochemical Core Lab (Rochester,
197 MN); the intra-assay CV was 3.5% at 2.50 ng/mL and 3.2% at 14.8 ng/mL. The inter-assay
198 CV's were 4.3% at 3.03 ng/mL, 5% at 7.23 ng/mL, and 4.8% at 13.62 ng/mL. All GH samples
199 from each subject were analyzed via batch in the same lab. Free IGF-1 was determined using a
200 commercially available ELISA (R & D systems; Minneapolis, MN) with a minimum detectable
201 range of 0.015 ng/mL, intra-assay CV 3.6-5% and inter-assay CV 10.0-11.1%. Total IGF-1 was
202 analyzed by Luminex® assay (Millipore Sigma; Burlington, MA), calibrated against the NIBSC
203 WHO IS 02/254, with an intra-assay CV <10% and inter-assay CV <15%. IGF binding protein-1
204 (IGFBP-1) and IGFBP-3 were analyzed by commercially available ELISAs (RayBiotech;
205 Norcross GA) with a minimum detectable concentration of 5 pg/mL for IGF-BP1 and 80 pg/mL
206 for IGF-BP3. Both assays report an intra-assay CV <10% and inter-assay CV <12%. tPA
207 activity and plasminogen activator inhibitor-1 (PAI-1) antigen were measured in blood collected
208 in acidified citrate anticoagulant (TriniLIZE™ Stabilyte tubes, Tcoag; Bray Co. Wicklow, Ireland).
209 TPA activity was analyzed using an ELISA calibrated against NIBSC WHO IS 98/714 (Oxford
210 Biomedical Research, Oxford MS). PAI-1 antigen was analyzed using the TintElize PAI-1
211 antigen assay (Tcoag; Co. Wicklow, Ireland). Samples for analysis of active GLP-1, total
212 peptide YY (PYY) and PYY 3-36, and glucagon were collected in EDTA collection tubes
213 prepared with aprotinin and DPP4 inhibitor (Millipore Sigma; Burlington, MA). Active GLP-1 was
214 analyzed in duplicate using the MILLEPLEX® MAP Human Metabolic Hormone Magnetic Bead

215 Panel (Millipore Sigma; Burlington, MA) with an intra-assay CV of <10% and inter-assay CV
216 <15%. Total PYY and PYY 3-36, glucagon, and insulin were analyzed in duplicate by
217 radioimmunoassay (Millipore Sigma; Burlington, MA) with intra-assay CVs of 3.7%, 2.3%, 1.6%,
218 and 3.3%, respectively. PYY 1-36 was calculated by subtracting PYY 3-36 from Total PYY.
219 Estradiol was also analyzed by radioimmunoassay (MP Biomedicals; Santa Ana, CA) with an
220 intra-assay CV of 3.9%. Blood glucoses were determined by Accu-Chek® Inform II bedside
221 glucometer (Roche Diagnostics; Indianapolis, IN); the same glucometer was used on each
222 outpatient study day. High-sensitivity C-reactive protein (hsCRP) was determined by
223 commercially available ELISA (Hycult®Biotech; Plymouth Meeting, PA). Bioavailable
224 testosterone was calculated from testosterone measured via quantitative high-performance
225 liquid chromatography-tandem mass spectrometry (ARUP® Laboratories; Salt Lake City, Utah).
226 Sex hormone binding globulin was obtained via quantitative electrochemiluminescent
227 immunoassay (ARUP® Laboratories; Salt Lake City, Utah). F2-isoprostanes were determined
228 via gas chromatography/mass spectrometry assay, as previously described.(25) Total plasma
229 cholesterol and triglycerides were measured by standard enzymatic assays. HDL cholesterol
230 was measured via the enzymatic method after precipitation of VLDL and LDL using
231 polyethylene glycol reagent. From these data LDL cholesterol was calculated using the
232 Friedewald equation. Plasma free fatty acids were analyzed with a commercially available
233 enzymatic kit (Wako Life Sciences; Richmond, VA). The insulinogenic index, quantitative insulin
234 sensitivity check index (QUICKI), homeostatic model assessment of insulin resistance (HOMA-
235 IR) and Matsuda Index were calculated as previously described. (26,27)

236

237 Analysis of Growth Hormone Secretion

238 Overnight spontaneous GH secretion was assessed using an automated deconvolution
239 algorithm (AutoDecon Pulse_XP Software Package), which determines secretion events, adds
240 them to the current fit to test for statistical significance, and automatically removes any non-
241 significant events until no additional statistically significant secretion events are found.(28)
242 AutoDecon has been validated for the analysis of endogenous pulsatile GH secretion from time-
243 series data obtained via frequent venous sampling from an indwelling catheter every ten
244 minutes for twelve hours.(29,30) Initial algorithm estimates included the standard deviation of
245 the secretion events, set at one-half of the data-sampling interval (5 min), and a starting value
246 for the GH elimination half-life of 13 minutes based upon previously published data in adults
247 with BMI >25 kg/m².(31) Initial values for basal secretion and concentration at t=0 were also
248 estimated from the secretion and concentration panels. AutoDecon then determined GH basal
249 secretion, half-life, median pulse mass and interpulse interval, number of GH peaks, and GH
250 area under the curve. Additional parameters of GH secretion including mean overnight GH
251 secretion, GH peak and nadir were determined via Microsoft Excel 2010. Missing data were
252 omitted from analyses.

253

254 Statistical Analysis

255 Data are presented in results tables as both mean ± standard deviation and median
256 [interquartile range, IQR], given that data is not normally distributed. We tested for carry-over
257 effect using the T-test approach proposed by Jones and Kenward.(32) Repeated measurement
258 continuous variable data from OGTT were summarized as mean over time (from baseline to 270
259 minutes) or area-under-the- curve (AUC) for the same time period. Unless otherwise noted, a
260 paired t-test was used to compare variables between treatment conditions with results
261 presented as the mean difference between treatments with 95% confidence interval (CI). Mixed

262 effect models were also used to analyze repeated measures data during the OGTT with a
263 random subject effect and with fixed effects of treatment (sitagliptin vs placebo), time and
264 treatment x time interaction. The baseline measurement was also included in each model.
265 Interaction terms were removed from the final model when the corresponding p value was >0.2.
266 Comparisons between treatments were made at each time-point using Wilcoxon signed rank
267 test. Spearman correlation was used to evaluate the association between continuous variables.
268 Analyses were performed using IBM SPSS software v. 23.0, GraphPad Prism 5 and R 2.15.0
269 (www.r-project.org). A p-value less than or equal to 0.05 was determined to be significant.

270

271 Sample Size Calculation

272 Sample size was calculated with Power and Sample Size Calculation (PS) Software using the
273 design for a paired t-test.(33) In a prior study mean baseline overnight GH was $0.7 \pm \text{SEM } 0.2$
274 $\mu\text{g/L}$ versus a mean overnight GH after therapy of $1.2 \pm \text{SEM } 0.3 \mu\text{g/L}$ ($p < 0.005$) in 13
275 subjects.(31) With the enrollment of subjects in current study, we found that the standard
276 deviation (SD) of mean overnight GH was $0.51 \mu\text{g/L}$ (measurements from two periods
277 combined), well below the SD of $0.72 \mu\text{g/L}$ and $1.1 \mu\text{g/L}$ observed in the prior study used in the
278 original sample size calculation. Conservatively assuming a SD of $0.6 \mu\text{g/L}$ in each group, we
279 calculated that a sample size of 16 women provides 93.2% power to detect a difference in GH
280 means of $0.5 \mu\text{g/L}$.

281

282 **Results**

283 Effect of sitagliptin on DPP4 activity and glucose metabolism

284 Seventeen women completed the entire study. One woman completed two weeks of both
285 treatments and is also included in the analysis of the outpatient study days.(Figure 1) Sitagliptin

286 100 mg daily significantly decreased DPP4 activity ($p < 0.001$ vs. placebo), as assessed on both
287 the outpatient visit days (from 21.3 ± 8.0 to 8.8 ± 5.2 nmol/mL per minute) and the inpatient visit
288 days (from 22.9 ± 6.0 to 9.9 ± 4.9 nmol/mL per minute).

289

290 Sitagliptin decreased blood glucose following ingestion of 75 grams of oral glucose, as
291 summarized as both average over time (mean difference -5.13 mg/dL, 95% CI $[-10.26, 0.00]$;
292 $p = 0.05$), and AUC (mean difference -1476.25 mg/dL x 120 min, 95% CI $[-2472.69, -479.81]$;
293 $p < 0.01$) (**Figure 3A**). Peak blood glucose following the oral glucose load was also lower during
294 sitagliptin treatment (mean difference -17.2 mg/dL, 95% CI $[-27.7, -6.6]$; $p < 0.01$). The overall
295 effect of sitagliptin on metabolism of glucose varied with time ($p < 0.001$). At 100 minutes, mean
296 blood glucose was 15.4 mg/dL (95% CI $8.7, 22.1$; $p < 0.001$) lower during sitagliptin treatment
297 than during placebo.

298

299 Sitagliptin also enhanced early insulin secretion, as demonstrated by an increase in the
300 insulinogenic index (from 1.9 ± 1.2 to 3.2 ± 3.1 ; $p = 0.02$) and insulin AUC for the first 30 minutes
301 after glucose ingestion (mean difference 349.21 μ U/mL x 30 min, 95% CI $[39.3, 659.1]$; $p = 0.05$)
302 (**Figure 3B**). Sitagliptin did not affect peripheral insulin resistance (Matsuda), hepatic insulin
303 resistance (HOMA-IR) or insulin sensitivity (QUICKI), as determined on the day of the 75-gram
304 OGTT (**Table 2**). Sitagliptin did not affect fasting blood glucose ($p = 0.572$ vs. placebo) or fasting
305 insulin levels ($p = 0.687$ vs. placebo).

306

307 Sitagliptin increased fasting GLP-1 levels ($p < 0.001$ vs. placebo) as well as GLP-1 levels during
308 the 75-gram OGTT, summarized as average over time (mean difference 27.01 pg/mL, 95% CI

309 [18.01, 36.01]; $p < 0.001$) (**Figure 4A**). Sitagliptin also increased peptide YY 1-36 (mean
310 difference 14.97 pg/mL, 95% CI [2.30, 27.63]; $p = 0.02$) and decreased peptide YY 3-36 (mean
311 difference -39.78 pg/mL, 95% CI [-51.39, -28.17]; $p < 0.001$). (**Figure 4B and C**) Sitagliptin did
312 not influence the change in free fatty acid levels or glucagon levels following oral glucose
313 ingestion (data not shown).

314

315 Effect of sitagliptin on GH secretion and IGF-1 levels

316 Overnight GH secretion (GH AUC) correlated inversely with weight (placebo: $r_s = -0.69$, $p = 0.003$;
317 sitagliptin: $r_s = -0.71$, $p = 0.002$), VAT mass (placebo: $r_s = -0.82$, $p < 0.001$; sitagliptin: $r_s = -0.77$,
318 $p = 0.001$), high-sensitivity C-reactive protein (placebo: $r_s = -0.53$, $p = 0.035$; sitagliptin: $r_s = -0.54$,
319 $p = 0.031$), and HOMA-IR (placebo: $r_s = -0.54$, $p = 0.033$; sitagliptin: $r_s = -0.79$, $p = 0.001$), regardless
320 of drug treatment during the preceding month.

321

322 GH levels were appropriately suppressed following oral glucose ingestion and then increased
323 approximately 4 hours later. Sitagliptin did not significantly influence the late GH peak (mean
324 difference 0.31 ng/mL, 95% CI [-0.92, 1.54]; $p = 0.61$) during the 75-gram OGTT. IGFBP-1
325 levels, summarized as average of time, were not affected by sitagliptin (mean difference -9.18
326 pg/mL, 95% CI [-104.73, 86.38]; $p = 0.84$). Free IGF-1 levels also were unaffected by sitagliptin
327 (mean difference -0.01 ng/mL, 95% CI [-0.09, 0.07]; $p = 0.84$). Free IGF-1 levels at each time
328 point following oral glucose were: baseline 0.46 ± 0.22 ng/mL placebo vs. 0.44 ± 0.21 ng/mL
329 sitagliptin; 30 minutes after oral glucose 0.46 ± 0.19 ng/mL placebo vs. 0.43 ± 0.18 ng/mL
330 sitagliptin; 90 minutes after oral glucose 0.44 ± 0.20 ng/mL placebo vs. 0.46 ± 0.20 ng/mL
331 sitagliptin; 150 minutes after oral glucose 0.49 ± 0.26 ng/mL placebo vs. 0.45 ± 0.22 ng/mL
332 sitagliptin.

333

334 During overnight sampling after one month of sitagliptin, GH half-life ($p=0.04$ vs. placebo) and
335 consequently the median interpulse interval ($p<0.05$ vs. placebo) both increased, but GH AUC
336 and mean GH were stable (**Table 3**). Representative plots of overnight sampling of GH from 3
337 subjects are included in **Figure 5**. One month of daily sitagliptin had no effect on fasting free
338 IGF-1 levels, total IGF-1 levels, or IGFBP-3 levels (**Table 3**).

339

340 Effect of sitagliptin on vascular parameters and conduit artery vascular function

341 Sitagliptin increased heart rate during the 75-gram OGTT summarized as average over time
342 (mean difference 2 bpm, 95% CI [0.01, 4.06]; $p<0.05$) and during the inpatient study day (from
343 67.4 ± 9.3 to 71.3 ± 6.9 bpm; $p<0.05$). One month of sitagliptin did not affect inflammatory or
344 fibrinolytic markers. Sitagliptin also had no effect on conduit artery vascular function during
345 reactive hyperemia. (**Table 4**) A limited number of women ($N=3$) met criteria for assessment of
346 endothelium-independent vasodilation using nitroglycerin and agreed to its administration.
347 Sitagliptin did not influence vasodilation after 0.4 mg sublingual nitroglycerin ($36.5\% \pm 13.7$ after
348 placebo vs. $36.4\% \pm 9.0$ after sitagliptin, $p>0.05$).

349

350 Effect of sitagliptin on body composition and characteristics of PCOS

351 One month of sitagliptin therapy decreased VAT mass ($p=0.02$ vs. placebo) and volume ($p=0.02$
352 vs. placebo), but did not significantly affect weight or overall percent fat (**Table 5**). Sitagliptin
353 decreased total cholesterol (from 168.8 ± 26.3 to 162.5 ± 22.2 mg/dL; $p=0.02$) largely due to a
354 decrease in LDL (from 101.9 ± 23.8 to 96.2 ± 21.5 mg/dL; $p=0.06$). One-month treatment with
355 sitagliptin did not influence estradiol or testosterone levels (**Table 5**). Sitagliptin did not affect

356 health-related quality of life domains (emotions, body hair, weight, infertility and menstrual
357 problems), as assessed by PCOS Questionnaire administered on the last day of each therapy
358 ($p=1.00$ vs. placebo for each domain).

359

360 Association between DPP4 inhibition and GH levels, VAT, and HOMA-IR

361 Sitagliptin did not increase overnight GH secretion or lower insulin resistance. Greater DPP4
362 inhibition in response to sitagliptin, however, correlated with GH levels, VAT and HOMA-IR.
363 The degree of DPP4 inhibition with sitagliptin correlated with GH secretion, such that DPP4
364 inhibition was associated with overnight GH secretion (GH AUC: $r_s= 0.60$, $p=0.02$; mean GH: $r_s=$
365 0.59 , $p=0.02$). DPP4 inhibition after sitagliptin was also associated with VAT mass ($r_s= -0.66$;
366 $p<0.01$), and HOMA-IR ($r_s=-0.64$; $p=0.01$). The correlations between DPP4 inhibition and GH
367 AUC, VAT, and HOMA-IR were no longer significant after controlling for BMI (GH AUC $r_s=0.25$,
368 $p=0.38$; VAT $r_s=-0.31$, $p=0.25$; HOMA-IR $r_s=-0.15$; $p=0.61$) . Women with higher DPP4 inhibition
369 during sitagliptin treatment, i.e. those in whom the percent DPP4 inhibition (defined as $[1-(\text{DPP4}$
370 $\text{activity during sitagliptin}/\text{DPP4 activity during placebo})]*100$) was above the median for the
371 women analyzed, had higher overnight GH secretion and lower VAT mass and HOMA-IR.
372 **Figure 6** compares values between those with higher DPP4 inhibition and lower DPP4 inhibition
373 within the sitagliptin treatment. Similarly, women with greater DPP4 inhibition also had lower
374 BMI (30.3 ± 3.4 vs. 38.5 ± 6.3 kg/m^2 ; $p<0.01$).

375

376 Safety

377 One woman was hospitalized with gallstone-induced pancreatitis after two doses of sitagliptin.
378 One woman reported intermittent abdominal pain while taking sitagliptin and another reported

379 dizziness. One woman taking sitagliptin reported dizziness towards the end of the OGTT,
380 another woman taking sitagliptin developed headache during the OGTT. There were no
381 reported instances of hypoglycemia while taking sitagliptin. Three woman reported nausea,
382 decreased appetite, and dizziness while taking placebo. One woman developed nausea during
383 the OGTT while taking placebo, and one experienced emesis. One woman developed shingles
384 while taking placebo. One woman developed headache, nausea, and dizziness following
385 nitroglycerin.

386

387 **Discussion**

388 This study tested the hypothesis that one-month treatment with the DPP4 inhibitor sitagliptin
389 would potentiate overnight GH secretion in overweight women with PCOS and improve glucose
390 levels. As expected, sitagliptin lowered blood glucose by increasing GLP-1 levels and
391 enhancing early insulin secretion following ingestion of oral glucose. Sitagliptin did not increase
392 mean overnight GH but did enhance GH half-life. Body composition also improved during
393 sitagliptin, as evidenced by a decrease in VAT, while weight and BMI remained stable. These
394 findings indicate that DPP4 inhibition with sitagliptin decreases the maximal glucose response to
395 OGTT, improves body composition, and increases GH half-life in overweight women with
396 PCOS.

397

398 Altered GLP-1 and insulin secretion following oral glucose ingestion has previously been
399 reported even in lean, glucose-tolerant women with PCOS. Women with PCOS have higher
400 levels of c-peptide and tend to have higher levels of insulin secretion particularly in the first hour
401 after glucose ingestion. While active GLP-1 levels are similar in women with PCOS and healthy
402 volunteers early on, they are lower in women with PCOS after one hour.(34) The glucagon

403 response to hypoglycemia is also potentiated in obese women with PCOS as compared to
404 matched controls.(35) We hypothesized that sitagliptin, with its ability to potentiate post-
405 prandial GLP-1 secretion and suppress glucagon secretion, would mitigate these undesirable
406 post-glucose changes. We observed enhanced GLP-1 secretion during sitagliptin, but no
407 changes in glucagon levels.

408

409 Only one previous study has evaluated the effect of sitagliptin on glucose homeostasis in
410 women with PCOS. Ferjan et al. conducted a 12-week study of obese women with PCOS in
411 which women were randomized to open label sitagliptin 100 mg daily with lifestyle intervention
412 or lifestyle intervention alone following metformin withdrawal.(36) The investigators found that
413 sitagliptin improved beta cell function and even prevented the conversion from impaired glucose
414 tolerance to type 2 diabetes mellitus in three of the women. The investigators did not appreciate
415 a significant decrease in glucose levels during OGTT. In contrast, we observed that sitagliptin
416 enhanced GLP-1 secretion following oral glucose ingestion which resulted in enhanced early
417 insulin secretion and a significant decrease in the blood glucose rise following oral glucose
418 ingestion. Our relatively more homogeneous study population and cross-over design likely
419 enabled us to detect better an improvement in blood glucose levels.

420

421 The effect of sitagliptin on post-prandial GH secretion has not previously been investigated. It is
422 well known that oral glucose ingestion quickly inhibits GH secretion before a late stimulatory
423 effect on GHRH-mediated GH levels. Relatively little is known, however, about the metabolic
424 factors that influence GH secretion following oral glucose. Grottoli et al. demonstrated that early
425 GH inhibition following glucose ingestion is lost in obesity but the late stimulatory effect is
426 maintained.(37) Iranmanesh et al further demonstrated that nadir and peak rebound GH

427 secretion is influenced by VAT and SHBG in obese men.(38) Potential mechanisms by which
428 sitagliptin might alter the GH secretion in response to an OGTT in women with PCOS include
429 enhanced late GH secretion due to decreased degradation of the GHRH stimulus or mitigation
430 of the known inhibitory effects of hyperglycemia and free fatty acids on GH secretion. Although
431 sitagliptin lowered blood glucoses following oral glucose ingestion, we did not observe any
432 effect of sitagliptin on free fatty acids or on GH secretion. Skov et al also demonstrated that
433 intravenous GLP-1 infusion in men reduces IGFBP-1 and tended to increase IGF-1
434 bioactivity.(39) We did see an increase in GLP-1 and early insulin secretion, but this did not
435 significantly influence IGFBP-1 levels or free IGF-1 levels. Thus, it is unlikely that alterations in
436 insulin secretion, blood glucoses, IGFBP-1, or GLP-1 levels contribute to the altered post-
437 glucose GH secretion described in obesity. Furthermore, IGF-1 did not contribute to the
438 observed changes in glucose metabolism in our study participants.

439

440 Our study investigates a novel potential strategy to enhance endogenous GH secretion in a
441 population of patients demonstrated to have diminished GH levels. Obese individuals have
442 diminished GH secretion, characterized by fewer GH pulses and shorter half-life duration.(40)
443 De Boer et. al. observed impaired overnight GH secretion in PCOS patients, irrespective of
444 weight and degree of insulin resistance.(12) We found that one month of sitagliptin therapy
445 influences overnight GH secretion by increasing GH half-life. The inter-pulse interval, which
446 represents the time interval between secretion events and is partially dependent upon half-life in
447 addition to the previous inter-pulse interval and secretion event area, was also
448 increased.(28,29) Sitagliptin did not increase overnight GH levels. Although overnight GH
449 secretion correlated with DPP4 inhibition after sitagliptin. this was not the case after controlling
450 for BMI.

451

452 Our study was not designed to determine the mechanism by which sitagliptin influences the
453 overnight GH secretory profile. Possible mechanisms include decreased degradation of the
454 GHRH stimulus by DPP4, or increased GH as an indirect result of decreased VAT. In support
455 of the first mechanism, Makimura et. al. reported that twelve months of the DPP4-resistant
456 GHRH analogue, tesamorelin, increases IGF-1 and selectively decreases VAT in obese
457 subjects with reduced GH secretion.(41) In contrast, we did not find that sitagliptin affected IGF-
458 1 levels, yet VAT was still selectively affected. The lack of effect of sitagliptin on IGF-1 levels is
459 not surprising given that sitagliptin did not affect overnight GH secretion. In support of the
460 second mechanism, Vahl et al found that abdominal obesity was the single most significant
461 determinant of pulsatile GH release, as determined by twenty-four hour GH profile.(42) Pijl et.
462 al. studied the effect of caloric restriction and 50% loss of body weight over a 3 to 5 month
463 period in obese women and observed an increase in mean 24 hour GH secretion.(6) Similar to
464 our findings, they observed an increase in GH half-life with no effect on IGF-1 levels. This
465 report is consistent with our observation of a smaller yet significant decrease in VAT and
466 increase in GH half-life after only one month of sitagliptin in our subjects. Dichtel LE et al
467 reported that in overweight and obese women, increases in bioactive IGF-1, rather than total
468 IGF-1, drive GH-mediated body composition changes in the short-term.(43) A decrease in GH
469 binding protein may also have played a role in the observed changes in GH half-life and inter-
470 pulse interval, as levels of GH binding protein directly correlate with VAT.(44) Lastly, another
471 mechanism possibly contributing to the decrease in VAT may be increased sympathetic activity.
472 We have previously reported that sitagliptin increases sympathetic activity during concurrent
473 angiotensin converting-enzyme (ACE) inhibition by decreasing degradation of the DPP4 and
474 ACE substrate substance P.(45) We did observe an increase in heart rate following sitagliptin
475 during the OGTT.

476

477 Others have reported that the addition of sitagliptin to metformin therapy improves body
478 composition in women with PCOS. Yan J et al reported that the addition of sitagliptin to
479 metformin treatment reduces VAT in patients with type 2 diabetes and non-alcoholic fatty liver
480 disease.(46) Ferjan et. al. similarly found that sitagliptin prevents weight regain, as compared to
481 metformin alone, in a 12-week prospective open label study in 24 obese women with PCOS
482 previously treated with liraglutide.(47) Thus, a growing body of evidence suggests that
483 sitagliptin selectively reduces VAT. Despite the improvements in VAT and GH secretion, we did
484 not observe an improvement in any of the clinical signs or symptoms experienced by women
485 with PCOS, as reported in a validated PCOS questionnaire. Longer duration of therapy would
486 likely be necessary to detect a change in these parameters. Similarly, androgen levels were not
487 affected by sitagliptin. We would expect androgen levels to improve in association with an
488 improvement in insulin resistance, and the latter was not observed.

489

490 Our study further evaluates cardiovascular endpoints, such as vascular function and fibrinolysis,
491 which may be affected by enhanced GH secretion. GH directly improves vascular function
492 through several mechanisms, including activation of the GH receptor and downstream IGF-1
493 secretion (48), as well as GH receptor- and IGF-1-independent effects.(49) Li et. al. reported
494 that supra-physiologic circulating concentrations GH of approximately 33 ng/mL were necessary
495 to increase forearm blood flow.(1) Similarly, Napoli et al reported that intra-arterial GH infusion,
496 which raised local GH to approximately 40 ng/mL, increased forearm blood flow.(2) We
497 previously reported that sitagliptin increases forearm vasodilation, measured by strain gauge
498 plethysmography, in healthy women as assessed during stimulated GH secretion with peak
499 levels averaging 11.6 mg/dL.(11) In the present study, we did not observe any effect of

500 sitagliptin on conduit artery vascular function, however. Mean overnight GH levels in this study
501 in patients with PCOS were significantly lower than in our prior study in healthy women. The
502 changes in GH secretion induced by sitagliptin may have been insufficient to detect an effect on
503 forearm vasodilation. Other potential factors, such as increased sympathetic activity due to
504 decreased degradation of other DPP4 substrates such as substance P and neuropeptide Y,
505 may also have masked any GH-induced changes in vascular function.(45,50) It is also notable
506 that we did not observe any increase in vasodilation despite elevated GLP-1 levels during
507 sitagliptin. This is consistent with our previous observation that GLP-1 infusion into the forearm
508 vasculature does not increase vasodilation.(51)

509

510 We report for the first time the effect of chronic sitagliptin treatment on tPA activity and PAI-1
511 antigen levels. Despite the observed decrease in VAT and cholesterol, there was no significant
512 effect of sitagliptin on PAI-1. This contrasts with the data of Tani et al who found that eight-
513 week treatment with vildagliptin decreased triglycerides and PAI-1 in poorly controlled type 2
514 diabetic patients.(52) The investigators suggested that improved lipid metabolism resulted in
515 down-regulation of PAI-1 production from the vascular endothelial cells. Triglyceride and PAI-1
516 levels in the women in the current study were one-third of the levels in their study population,
517 thus making it difficult to detect further down-regulation of PAI-1 production. We have
518 previously demonstrated that GH affects tPA activity levels through the GH receptor and
519 downstream IGF-1 secretion,(11) but we did not observe any change in IGF-1 or tPA activity in
520 this study. We also did not see any effect of sitagliptin on inflammation, whereas Makdissi A et
521 al observed an anti-inflammatory effect of 100 mg daily sitagliptin on CRP, IL-6 and free fatty
522 acids after 12 weeks in patients with type 2 diabetes.(53) Differences in study populations or
523 treatment duration could account for these different observations.

524

525 Our study has limitations. PCOS is a heterogeneous disorder; women may be lean or
526 overweight and may or may not have insulin resistance. We studied a relatively homogenous
527 subset of women with PCOS and our results may not be generalizable to all women with PCOS.
528 We chose to limit our study population to those women with a BMI of at least 25 kg/m² and to
529 exclude participants who were dieting with weight loss or titrating metformin therapy. This
530 subset of women with PCOS tends to represent the subset who are prescribed metformin in
531 order to improve glucose metabolism. We were interested in how sitagliptin influenced glucose
532 metabolism in overweight women with PCOS and we were limited to use of a manual
533 glucometer for glucose measurements, though the same glucometer was used for each woman
534 across study days. We also did not include baseline endogenous GH secretory capacity as a
535 selection criterion for the women studied, as is done in many clinical trials evaluating the effect
536 of an intervention on GH secretion. If we had pre-selected for a relatively GH-deficient
537 population, we may have seen a more prominent effect of sitagliptin on overnight GH secretion.
538 We were unable to standardize timing of the endpoint measurements to womens' menstrual
539 cycles, as most women had infrequent menstrual cycles. This is particularly relevant in our
540 assessments of overnight GH secretion and vascular function. We did not observe a difference
541 in estradiol levels across study treatments, however. Our treatment duration was one month,
542 which may not have been sufficient to appreciate any effect of sitagliptin on clinical symptoms,
543 or inflammatory or fibrinolytic markers. We chose to use the current FDA-approved daily dose
544 of sitagliptin, however we have previously demonstrated that 100 mg daily of sitagliptin is not as
545 effective as single-dose 200 mg sitagliptin in inhibiting DPP4 activity in healthy individuals, and
546 that sitagliptin 100 mg daily is less effective in inhibiting DPP4 activity in individuals with type 2
547 diabetes mellitus and hypertension than in healthy individuals.(54) A higher dose of sitagliptin
548 resulting in maximal DPP4 inhibition may have yielded a greater treatment effect on mean GH

549 and eliminated any effect of weight on response to sitagliptin. Our limited sample size may
550 have limited our conclusions on overnight GH secretion parameters. We observed low intra-
551 individual variability in the pattern of overnight GH secretion, however, and the cross-over
552 design of the study would have increased our ability to detect treatment effects. Lastly, our
553 study design did not enable us to determine the mechanism by which sitagliptin may enhance
554 GH half-life.

555

556 In this study, we evaluated the previously unexplored effects of sitagliptin in overweight women
557 with PCOS. We demonstrate for the first time that sitagliptin enhances GLP-1 levels and early
558 insulin secretion and thereby decreases peak blood glucose following oral glucose ingestion in
559 these women. Second, we demonstrate that sitagliptin improves body composition, through an
560 undefined mechanism. As weight loss remains the cornerstone of treatment for PCOS, this is
561 also a highly desirable effect. Lastly, this study is the first to suggest an off-target effect of
562 sitagliptin on GH secretion in women with PCOS, potentiating GH half-life and the inter-pulse
563 interval. This is relevant as endogenous GH secretion is diminished in women with PCOS. (12-
564 14) These data are the first to support the use of oral DPP4 inhibitor therapy to address
565 elevated blood glucoses and body composition in women with PCOS, and to probe the
566 contribution of an altered somatotrophic axis in the pathophysiology of this common disorder.

567 **Acknowledgements:**

568 We thank Anthony Dematteo, Zuofei Wang, and Aaron Falck for their technical assistance. We
569 thank Drs. Kevin Niswender, Italo Biaggioni, and Melissa Wellons for their expertise and service
570 on the Data and Safety Monitoring Committee.

571

572

References

- 573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
1. Li G, Del Rincon JP, Jahn LA, Wu Y, Gaylinn B, Thorner MO, Liu Z. Growth hormone exerts acute vascular effects independent of systemic or muscle insulin-like growth factor I. *The Journal of clinical endocrinology and metabolism* 2008; 93:1379-1385
 2. Napoli R, Guardasole V, Angelini V, D'Amico F, Zarra E, Matarazzo M, Sacca L. Acute effects of growth hormone on vascular function in human subjects. *The Journal of clinical endocrinology and metabolism* 2003; 88:2817-2820
 3. Sesmilo G, Biller BM, Llevadot J, Hayden D, Hanson G, Rifai N, Klibanski A. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. *Ann Intern Med* 2000; 133:111-122
 4. Devin JK, Blevins LS, Jr., Verity DK, Chen Q, Bloodworth JR, Jr., Covington J, Vaughan DE. Markedly impaired fibrinolytic balance contributes to cardiovascular risk in adults with growth hormone deficiency. *The Journal of clinical endocrinology and metabolism* 2007; 92:3633-3639
 5. Miljic D, Miljic P, Doknic M, Pekic S, Stojanovic M, Cvijovic G, Micic D, Popovic V. Growth hormone replacement normalizes impaired fibrinolysis: new insights into endothelial dysfunction in patients with hypopituitarism and growth hormone deficiency. *Growth Horm IGF Res* 23:243-248
 6. Pijl H, Langendonk JG, Burggraaf J, Frolich M, Cohen AF, Veldhuis JD, Meinders AE. Altered neuroregulation of GH secretion in viscerally obese premenopausal women. *The Journal of clinical endocrinology and metabolism* 2001; 86:5509-5515
 7. Jorgensen JO, Moller L, Krag M, Billestrup N, Christiansen JS. Effects of growth hormone on glucose and fat metabolism in human subjects. *Endocrinol Metab Clin North Am* 2007; 36:75-87
 8. Frohman LA, Downs TR, Heimer EP, Felix AM. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. *J Clin Invest* 1989; 83:1533-1540
 9. Frohman LA, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH₂ terminus. *J Clin Invest* 1986; 78:906-913
 10. Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. *Clin Ther* 2006; 28:55-72
 11. Wilson JR, Brown NJ, Nian H, Yu C, Bidlingmaier M, Devin JK. Dipeptidyl Peptidase-4 Inhibition Potentiates Stimulated Growth Hormone Secretion and Vasodilation in Women. *J Am Heart Assoc* 7
 12. de Boer JA, Lambalk CB, Hendriks HH, van Aken C, van der Veen EA, Schoemaker J. Growth hormone secretion is impaired but not related to insulin sensitivity in non-obese patients with polycystic ovary syndrome. *Hum Reprod* 2004; 19:504-509
 13. Orio F, Jr., Palomba S, Colao A, Russo T, Dentico C, Tauchmanova L, Savastano S, Nappi C, Sultan C, Zullo F, Lombardi G. GH release after GHRH plus arginine administration in obese and overweight women with polycystic ovary syndrome. *J Endocrinol Invest* 2003; 26:117-122
 14. Piaditis GP, Kounadi TG, Rangou DB, Trovas GP, Kaklas NA, Tzonou AJ, Chlouverakis CS. Dysfunction of the growth hormone/insulin-like growth factor-I axis in women with polycystic ovarian syndrome. *Clin Endocrinol (Oxf)* 1995; 42:635-640

- 622 **15.** Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden
623 of the polycystic ovary syndrome during the reproductive life span. *The Journal of clinical*
624 *endocrinology and metabolism* 2005; 90:4650-4658
- 625 **16.** Use of insulin sensitizing agents in the treatment of polycystic ovary syndrome. *Fertil*
626 *Steril* 2004; 82 Suppl 1:S181-183
- 627 **17.** Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary
628 syndrome. *Clin Epidemiol* 2013; 6:1-13
- 629 **18.** Rotterdam EA-SPCWG. Revised 2003 consensus on diagnostic criteria and long-term
630 health risks related to polycystic ovary syndrome. *Fertil Steril* 2004; 81:19-25
- 631 **19.** Cronin L, Guyatt G, Griffith L, Wong E, Azziz R, Futterweit W, Cook D, Dunaif A.
632 Development of a health-related quality-of-life questionnaire (PCOSQ) for women with
633 polycystic ovary syndrome (PCOS). *The Journal of clinical endocrinology and*
634 *metabolism* 1998; 83:1976-1987
- 635 **20.** Guyatt G, Weaver B, Cronin L, Dooley JA, Azziz R. Health-related quality of life in
636 women with polycystic ovary syndrome, a self-administered questionnaire, was
637 validated. *J Clin Epidemiol* 2004; 57:1279-1287
- 638 **21.** Jones GL, Benes K, Clark TL, Denham R, Holder MG, Haynes TJ, Mulgrew NC,
639 Shepherd KE, Wilkinson VH, Singh M, Balen A, Lashen H, Ledger WL. The Polycystic
640 Ovary Syndrome Health-Related Quality of Life Questionnaire (PCOSQ): a validation.
641 *Hum Reprod* 2004; 19:371-377
- 642 **22.** Marinos A, Celedonio JE, Ramirez CE, Gottlieb J, Gamboa A, Hui N, Yu C, Stein CM,
643 Biaggioni I, Shibao CA. Time-Course Analysis of Flow Mediated Dilatation for the
644 Evaluation of Endothelial Function After a High-Fat Meal in African Americans. *J Am*
645 *Heart Assoc* 4
- 646 **23.** Black MA, Cable NT, Thijssen DH, Green DJ. Importance of measuring the time course
647 of flow-mediated dilatation in humans. *Hypertension* 2008; 51:203-210
- 648 **24.** Lefebvre J, Murphey LJ, Hartert TV, Jiao Shan R, Simmons WH, Brown NJ. Dipeptidyl
649 peptidase IV activity in patients with ACE-inhibitor-associated angioedema.
650 *Hypertension* 2002; 39:460-464
- 651 **25.** Milne GL, Gao B, Terry ES, Zackert WE, Sanchez SC. Measurement of F2-
652 isoprostanes and isofurans using gas chromatography-mass spectrometry. *Free Radic*
653 *Biol Med* 2013; 59:36-44
- 654 **26.** Singh B, Saxena A. Surrogate markers of insulin resistance: A review. *World J Diabetes*
655 2010; 1:36-47
- 656 **27.** Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose
657 tolerance testing: comparison with the euglycemic insulin clamp. *Diabetes Care* 1999;
658 22:1462-1470
- 659 **28.** Johnson ML, Pipes L, Veldhuis PP, Farhy LS, Boyd DG, Evans WS. AutoDecon, a
660 deconvolution algorithm for identification and characterization of luteinizing hormone
661 secretory bursts: description and validation using synthetic data. *Anal Biochem* 2008;
662 381:8-17
- 663 **29.** Johnson ML, Pipes L, Veldhuis PP, Farhy LS, Nass R, Thorner MO, Evans WS.
664 AutoDecon: a robust numerical method for the quantification of pulsatile events.
665 *Methods Enzymol* 2009; 454:367-404
- 666 **30.** Veldhuis JD, Keenan DM. Model-based evaluation of growth hormone secretion.
667 *Methods Enzymol* 514:231-248
- 668 **31.** Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth
669 hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity
670 in healthy men. *The Journal of clinical endocrinology and metabolism* 96:150-158
- 671 **32.** Jones B KM. Design and Analysis of Crossover Trials. Boca Raton, FL: CRC Press LLC.

- 672 **33.** Dupont WD, Plummer WD, Jr. Power and sample size calculations. A review and
673 computer program. *Control Clin Trials* 1990; 11:116-128
- 674 **34.** Vrbikova J, Hill M, Bendlova B, Grimmichova T, Dvorakova K, Vondra K, Pacini G.
675 Incretin levels in polycystic ovary syndrome. *European journal of endocrinology* 2008;
676 159:121-127
- 677 **35.** Sam S, Vellanki P, Yalamanchi SK, Bergman RN, Dunaif A. Exaggerated glucagon
678 responses to hypoglycemia in women with polycystic ovary syndrome. *Metabolism:*
679 *clinical and experimental* 71:125-131
- 680 **36.** Ferjan S, Janez A, Jensterle M. Dpp4 Inhibitor Sitagliptin as a Potential Treatment
681 Option in Metformin-Intolerant Obese Women with Polycystic Ovary Syndrome: A Pilot
682 Randomized Study. *Endocr Pract* 2018; 24:69-77
- 683 **37.** Grottoli S, Procopio M, Maccario M, Zini M, Oleandri SE, Tassone F, Valcavi R, Ghigo E.
684 In obesity, glucose load loses its early inhibitory, but maintains its late stimulatory, effect
685 on somatotrope secretion. *The Journal of clinical endocrinology and metabolism* 1997;
686 82:2261-2265
- 687 **38.** Iranmanesh A, Lawson D, Veldhuis JD. Distinct metabolic surrogates predict basal and
688 rebound GH secretion after glucose ingestion in men. *The Journal of clinical*
689 *endocrinology and metabolism* 2012; 97:2172-2179
- 690 **39.** Skov J, Frystyk J, Christiansen JS. GLP-1 infusion reduces IGFBP-1 serum level in
691 humans. *Growth Horm IGF Res* 2014; 24:67-70
- 692 **40.** Veldhuis JD, Iranmanesh A, Ho KK, Waters MJ, Johnson ML, Lizarralde G. Dual defects
693 in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of
694 obesity in man. *The Journal of clinical endocrinology and metabolism* 1991; 72:51-59
- 695 **41.** Makimura H, Feldpausch MN, Rope AM, Hemphill LC, Torriani M, Lee H, Grinspoon SK.
696 Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced
697 growth hormone secretion: a randomized controlled trial. *The Journal of clinical*
698 *endocrinology and metabolism* 2012; 97:4769-4779
- 699 **42.** Vahl N, Jorgensen JO, Skjaerbaek C, Veldhuis JD, Orskov H, Christiansen JS.
700 Abdominal adiposity rather than age and sex predicts mass and regularity of GH
701 secretion in healthy adults. *Am J Physiol* 1997; 272:E1108-1116
- 702 **43.** Dichtel LE, Bjerre M, Schorr M, Bredella MA, Gerweck AV, Russell BM, Frystyk J, Miller
703 KK. The effect of growth hormone on bioactive IGF in overweight/obese women. *Growth*
704 *Horm IGF Res* 2018; 40:20-27
- 705 **44.** Fisker S, Vahl N, Jorgensen JO, Christiansen JS, Orskov H. Abdominal fat determines
706 growth hormone-binding protein levels in healthy nonobese adults. *The Journal of*
707 *clinical endocrinology and metabolism* 1997; 82:123-128
- 708 **45.** Devin JK, Pretorius M, Nian H, Yu C, Billings FTt, Brown NJ. Substance P increases
709 sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl
710 peptidase-4 inhibition. *Hypertension* 2014; 63:951-957
- 711 **46.** Yan J, Yao B, Kuang H, Yang X, Huang Q, Hong T, Li Y, Dou J, Yang W, Qin G, Yuan
712 H, Xiao X, Luo S, Shan Z, Deng H, Tan Y, Xu F, Xu W, Zeng L, Kang Z, Weng J.
713 Liraglutide, sitagliptin and insulin glargine added to metformin: the effect on body weight
714 and intrahepatic lipid in patients with type 2 diabetes mellitus and NAFLD. *Hepatology*
715 2018;
- 716 **47.** Ferjan S, Janez A, Jensterle M. Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented
717 Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated
718 with Liraglutide: A Pilot Randomized Study. *Metabolic syndrome and related disorders*
719 2017; 15:515-520
- 720 **48.** Thum T, Fleissner F, Klink I, Tsikas D, Jakob M, Bauersachs J, Stichtenoth DO. Growth
721 hormone treatment improves markers of systemic nitric oxide bioavailability via insulin-

- 722 like growth factor-I. The Journal of clinical endocrinology and metabolism 2007; 92:4172-
723 4179
- 724 **49.** Tivesten A, Barlind A, Caidahl K, Klintland N, Cittadini A, Ohlsson C, Isgaard J. Growth
725 hormone-induced blood pressure decrease is associated with increased mRNA levels of
726 the vascular smooth muscle KATP channel. J Endocrinol 2004; 183:195-202
- 727 **50.** Hubers SA, Wilson JR, Yu C, Nian H, Grouzmann E, Eugster P, Shibao CA, Billings FTt,
728 Jafarian Kerman S, Brown NJ. DPP (Dipeptidyl Peptidase)-4 Inhibition Potentiates the
729 Vasoconstrictor Response to NPY (Neuropeptide Y) in Humans During Renin-
730 Angiotensin-Aldosterone System Inhibition. Hypertension 72:712-719
- 731 **51.** Devin JK, Pretorius M, Nian H, Yu C, Billings FTt, Brown NJ. Dipeptidyl-peptidase 4
732 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide
733 in the human forearm. J Am Heart Assoc 2014; 3
- 734 **52.** Tani S, Takahashi A, Nagao K, Hirayama A. Effect of dipeptidyl peptidase-4 inhibitor,
735 vildagliptin on plasminogen activator inhibitor-1 in patients with diabetes mellitus. Am J
736 Cardiol 2015; 115:454-460
- 737 **53.** Makdissi A, Ghanim H, Vora M, Green K, Abuaysheh S, Chaudhuri A, Dhindsa S,
738 Dandona P. Sitagliptin exerts an antiinflammatory action. The Journal of clinical
739 endocrinology and metabolism 2012; 97:3333-3341
- 740 **54.** Wilson JR, Shuey MM, Brown NJ, Devin JK. Hypertension and Type 2 Diabetes Are
741 Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin. J Endocr
742 Soc 2017; 1:1168-1178

743

744

745 **Figure Legends**

746 **Figure 1. Participant Flow Diagram.** Fifty-five women with polycystic ovarian syndrome
747 (PCOS) were screened for study participation and 32 were determined to be eligible. Twenty-
748 three women agreed to participate and were randomized to study drug. Eighteen of these
749 women participated in both study arms and their data were included in analyses. Complete
750 data was available only from both outpatient visits in one woman. Another woman did not
751 complete the overnight GH sampling portion of both inpatient visits.

752 **Figure 2. Subjects participated in a double-blind, randomized, placebo-controlled,**
753 **crossover study.** Eighteen women underwent two one-month treatment periods (sitagliptin
754 100 mg p.o. qd or matching placebo) separated by a washout period of at least eight weeks. On
755 each study day, subjects reported to the Vanderbilt Clinical Research Center (CRC) in the
756 morning after an overnight fast. After approximately two weeks of study drug, subjects
757 underwent an extended OGTT (75-grams oral glucola). Women were then discharged and
758 continued daily study drug at home for an additional two weeks. On the last day of study drug,
759 women (N=17) again reported to the CRC for collection of fasting venous samples,
760 measurement of endothelium-dependent and -independent vasodilation, measurement of total
761 and regional body composition via dual-energy x-ray absorptiometry, and frequent venous
762 sampling for GH every ten minutes for twelve hours overnight.

763 **Figure 3. Sitagliptin improves blood glucoses (A) and early insulin secretion (B) following**
764 **75 grams oral glucose.** Data were obtained on the outpatient visit day in 18 women and are
765 presented as mean \pm SD. The overall effect of sitagliptin on glucose levels varied with time
766 ($p < 0.001$). P value was obtained via mixed effect model with a random subject effect and with
767 fixed effects of treatment (sitagliptin vs placebo), time and treatment x time interaction. * $p \leq 0.05$
768 vs. placebo at corresponding timepoint, as obtained by Wilcoxon signed rank.

769 **Figure 4. Sitagliptin increases both GLP-1 (A) and PYY 1-36 (B) and decreases PYY 3-36**
770 **(C) levels following oral 75 grams glucose.** Data were obtained on the outpatient visit day in
771 18 women, and are expressed as mean \pm SD. Model based p values for treatment effect are:
772 $p < 0.001$ for effect of sitagliptin on GLP-1, $p < 0.001$ for effect of sitagliptin on PYY 1-36, $p < 0.001$
773 for effect of sitagliptin on PYY 3-36. P value was obtained via mixed effect model with a random
774 subject effect and with fixed effects of treatment (sitagliptin vs placebo), time and treatment x
775 time interaction. * $p \leq 0.05$ vs. placebo at corresponding timepoint, as obtained by Wilcoxon
776 signed rank.

777 **Figure 5. Representative plots of overnight GH levels from 3 subjects during placebo and**
778 **sitagliptin treatment.** GH samples are obtained every 10 minutes from 8 PM to 8 AM. The
779 plots illustrate the high inter-individual variability but low intra-individual variability in overnight
780 GH secretion.

781 **Figure 6. Women with a higher percent DPP4 inhibition had higher overnight GH**
782 **secretion (A and B, N=16) and lower VAT mass (C, N=17) and HOMA-IR (D, N=17) after**
783 **one-month treatment with sitagliptin.** Data were obtained on the inpatient visit day and are
784 expressed as mean \pm SD. P values were calculated using the Wilcoxon rank sum test. Higher
785 percent DPP4 inhibition is defined as percent DPP4 inhibition at or greater than the median for
786 the 17 women included in the analysis, where percent DPP4 inhibition = $[1 - (\text{DPP4 activity during sitagliptin} / \text{DPP4 activity during placebo})] * 100$. Comparisons between higher and lower
787 DPP4 inhibition were not significant after controlling for BMI (GH AUC $p = 0.27$; mean GH
788 $p = 0.24$; VAT $p = 0.67$; HOMA-IR $p = 0.66$)
789

790

791 **Table 1. Subject Characteristics**

Variable	N=18
Age (years)	30.5 [7], 30.3 ± 3.3
Race	
White	13 (72%)
Black	3 (17%)
Asian	2 (11%)
Weight (kg)	81.0 [30.5], 90.6 ± 22.0
Body Mass Index (kg/m ²)	32.9 [10.9], 34.1 ± 6.4
Overweight (25.0-29.9)	5 (28%)
Class I (30.0-34.9)	6 (33%)
Class II (35.0-39.9)	3 (17%)
Class III (≥ 40)	4 (22%)
Waist Circumference (cm)	101.7 [16.7], 104.8 ± 13.6
Waist-Hip Ratio	0.9 [0.1], 0.9 ± 0.1
Systolic Blood Pressure (mm Hg)	123.0 [20.0], 120.7 ± 12.0
Diastolic Blood Pressure (mmHg)	78.5 [13.0], 77.3 ± 7.9
Heart rate (beats per minute)	77.0 [12.8], 77.2 ± 9.9
PCOS Diagnostic Criteria	
Oligomenorrhea	17 (94%)
Hyperandrogenemia (hirsutism)	16 (89%)
Polycystic Ovaries on Ultrasound	11 (61%)
Current Metformin Use	1 (6%)
Fasting Blood Glucose (mg/dL)	83.5 [12.8], 85.5 ± 9.2
Bioavailable testosterone LC-MS (ng/dl)*	20.2 [15.3], 18.6 ± 10.0
Corrected bioavailable testosterone*†	0.8 [0.8], 0.8 ± 0.5
Sex hormone binding globulin (nmol/L)	30.5 [60.3], 59.9 ± 65.6
(normal range 30-135)	

792 Data shown as median [interquartile range] and mean ± SD. *N=17. † Corrected bioavailable
793 testosterone=bioavailable testosterone/assay upper limit of normal for age group. 6/17 (35%)
794 had bioavailable testosterone levels above the upper limit of normal.

795 **Table 2. Effect of sitagliptin on glucose metabolism**

Outpatient Day (N=18)	Placebo	Sitagliptin	P-Value
Blood glucose, 0-120 min AUC	15971.3 [3148.1] 15353.8 ± 2708.6	13432.5 [3361.9] 13877.5 ± 2486.3	0.009
Blood glucose, 0-30 min AUC	3176.3 [371.3] 3192.1 ± 356.9	3108.8 [451.9] 3140.4 ± 421.3	0.913
Insulin 0-120 min AUC	8642.9 [5670.4] 11132.1 ± 8215.6	10031.1 [6878.2] 12169.3 ± 6568.3	0.212
Insulin 0-30 min AUC	1337.0 [763.8] 1522.1 ± 792.3	1663.1 [1130.6] 1871.3 ± 843.6	0.054
Insulinogenic index	1.84 [1.52] 1.89 ± 1.20	2.7 [3.4] 3.2 ± 3.1	0.016
Matsuda index	3.31 [2.51] 3.27 ± 1.54	2.96 [2.13] 3.17 ± 1.99	0.248
QUICKI	0.32 [0.03] 0.33 ± 0.03	0.32 [0.03] 0.32 ± 0.03	0.327
HOMA-IR	3.4 [2.3] 3.5 ± 1.8	3.1 [2.7] 4.0 ± 2.5	0.306
Inpatient Day (N=17)	Placebo	Sitagliptin	P-Value
Fasting blood glucose (mg/dL)*	93.0 [7.0] 92.9 ± 10.3	90.0 [9.0] 90.9 ± 5.7	0.572
Fasting insulin (µU/mL)	13.9 [6.9] 16.5 ± 10.9	14.8 [9.2] 17.6 ± 9.8	0.687
HOMA-IR*	3.2 [1.4] 3.9 ± 2.7	3.7 [2.6] 4.1 ± 2.1	0.691
Fasting glucagon (pg/mL)	48.8 [20.6] 48.2 ± 16.4	45.2 [19.6] 49.0 ± 21.4	0.906
Fasting GLP-1 (pg/mL)	8.2 [11.7] 9.8 ± 8.2	26.9 [16.4] 27.6 [13.8]	<0.001

Data shown as median [interquartile range] and mean ± SD. P values obtained via Wilcoxon signed rank test.* Data available in 15 women.

796 **Table 3. Effect of sitagliptin on overnight GH secretion and IGF-1 levels**

Variable (N=16)	Placebo	Sitagliptin	P-Value
GH AUC (ng/mL per 12 hr)	428.9 [543.5]	524.6 [466.0]	0.918
	604.5 ± 398.7	593.5 ± 371.6	
Basal GH secretion (ng/mL·min)*	0.001 [0.002]	0.002 [0.002]	0.496
	0.002 ± 0.002	0.002 ± 0.001	
GH half-life (min)	13.9 [2.7]	14.5 [8.0]	0.044
	13.9 ± 3.6	17.0 ± 6.8	
Number GH secretion events	10.5 [4.0]	8.5 [6.5]	0.058
	11.0 ± 2.6	9.1 ± 3.3	
Median secretion pulse mass	1.1 [1.2]	1.3 [1.8]	0.756
	2.2 ± 3.4	1.7 ± 1.5	
Median secretion pulse height	0.04 [0.05]	0.07 [0.16]	0.301
	0.10 ± 0.14	0.34 ± 0.63	
Median secretion interpulse interval	51.1 [34.4]	61.8 [60.6]	0.049
	53.2 ± 20.0	77.3 ± 38.2	
Maximum GH (ng/mL)	4.1 [5.5]	4.0 [3.5]	0.918
	5.1 ± 3.5	5.1 ± 4.4	
Minimum GH (ng/mL)	0.03 [0.03]	0.04 [0.05]	0.567
	0.04 ± 0.02	0.04 ± 0.02	
Mean GH (ng/mL)	0.63 [0.73]	0.74 [0.73]	0.918
	0.85 ± 0.54	0.84 ± 0.51	
Total IGF-1 (ng/mL)†	81.4 [57.0]	86.6 [52.1]	0.586
	88.7 ± 28.6	88.8 ± 29.7	
Free IGF-1 (ng/mL)†	0.31 [0.27]	0.38 [0.18]	0.523
	0.40 ± 0.26	0.43 ± 0.25	
IGFBP-1 (pg/mL)	184.4 [149.4]	158.2 [469.6]	0.326
	263.6 ± 298.3	325.2 ± 365.3	
IGFBP-3 (ng/mL)†	17.1 [5.9]	18.9 [3.4]	0.687
	18.5 ± 4.3	18.6 ± 2.4	
IGF-1/IGFBP-3†	4.8 [3.2]	4.4 [3.2]	0.906
	5.1 ± 2.2	4.9 [1.9]	

Data shown as median [interquartile range] and mean \pm SD. P values obtained via Wilcoxon signed rank test.*Data available in 15 women. † Data available in 17 women. IGF-1 and IGFBP represent morning fasting levels. GH levels were obtained every 10 minutes from 8 PM until 8 AM.

797

798

799 **Table 4. Effect of sitagliptin on vascular parameters and conduit artery vascular function**

Variable (N=17)	Placebo	Sitagliptin	P-Value
Systolic Blood Pressure (mm Hg)	114.7 [18.7] 117.8 ± 11.6	115.0 [16.2] 115.6 ± 8.7	0.518
Diastolic Blood Pressure (mmHg)	75.0 [8.9] 73.8 ± 7.4	73.0 [11.0] 73.7 ± 7.8	1.000
Heart rate (beats per minute)	67.0 [14.2] 67.4 ± 9.3	68.0 [7.0] 71.3 ± 6.9	0.046
Baseline artery diameter (mm)	3.14 [0.55] 3.16 ± 0.43	3.12 [0.62] 3.13 ± 0.37	0.796
Baseline flow integral (m)	0.12 [0.04] 0.15 ± 0.08	0.17 [0.07] 0.18 ± 0.08	0.266
Peak FMD (mm)	3.53 [0.66] 3.58 ± 0.47	3.48 [0.54] 3.53 ± 0.36	0.344
Time of peak FMD (sec)	59.00 [37.82] 60.71 ± 30.80	64.66 [46.56] 75.55 ± 35.02	0.356
Diameter increase (mm)	0.39 [0.26] 0.43 ± 0.16	0.40 [0.23] 0.40 ± 0.16	0.705
Flow-mediated vasodilation (%)	12.42 [8.28] 13.63 ± 5.27	14.24 [8.45] 13.00 ± 5.34	0.943
Peak VTI (m)*	1.13 [0.34] 1.12 ± 0.23	1.14 [0.27] 1.13 ± 0.32	0.717
VTI, fold increase*	8.37 [3.49] 8.34 ± 2.66	7.26 [4.35] 7.38 ± 2.79	0.234
tPA activity (IU/mL)	0.21 [0.40] 0.40 ± 0.47	0.23 [0.82] 0.44 ± 0.46	0.831
PAI-1 antigen (ng/mL)*	8.78 [7.33] 10.96 ± 7.51	9.72 [4.77] 11.27 ± 8.05	0.959
hsCRP (mg/L)	3.51 [4.40] 4.43 ± 4.00	2.90 [3.45] 4.92 ± 5.36	0.619
F2 Isoprostanes (pg/mL)*	55.74 [44.02] 68.16 ± 45.69	50.02 [42.26] 62.01 ± 30.25	0.836

800 Data shown as median [interquartile range] and mean \pm SD. P values obtained via Wilcoxon
801 signed rank test. *Data available in 16 women.


802 **Table 5. Effect of sitagliptin on body composition and characteristics of PCOS**


Variable (N=17)	Placebo	Sitagliptin	P-value
Weight (kg)	81.0 [28.0]	81.6 [27.1]	0.619
	90.4 ± 21.7	90.2 ± 22.1	
Body Mass Index (kg/m ²)	32.1 [10.7]	32.4 [10.4]	0.586
	34.3 ± 6.4	34.2 ± 6.4	
Waist Circumference (cm)	105.9 [27.7]	105.0 [18.7]	0.381
	105.5 ± 18.0	104.0 ± 15.4	
Waist-Hip Ratio*	0.89 [0.12]	0.87 [0.10]	0.326
	0.88 ± 0.07	0.87 ± 0.07	
Percent Body Fat (%)	46.2 [5.2]	45.8 [6.5]	0.058
	46.8 ± 5.4	46.3 ± 5.0	
Fat (kg)	36.4 [16.9]	35.5 [18.0]	0.093
	41.6 ± 14.3	40.9 ± 14.5	
Lean Body Mass (kg)	43.9 [10.1]	44.6 [10.4]	0.758
	45.6 ± 7.4	45.8 ± 7.9	
VAT Volume (cm ³)	1199.0 [744.0]	959.0 [820.5]	0.022
	1210.6 ± 743.0	1118.4 ± 752.5	
VAT Mass (g)	1131.0 [702.0]	904.0 [774.0]	0.022
	1141.9 ± 700.7	1055.1 ± 710.1	
Android (% fat)†	54.1 [9.2]	51.9 [11.2]	0.037
	54.0 ± 7.6	52.8 ± 7.0	
Bioavailable Testosterone (ng/dL)*	23.2 [11.5]	16.1 [12.0]	0.109
	22.9 ± 10.3	19.8 ± 10.5	
Total Testosterone (ng/dL)	43.0 [25.0]	36.0 [31.0]	0.266
	48.4 ± 24.3	45.1 ± 27.5	
SHBG (nmol/L)*	25.5 [20.0]	31.5 [18.8]	0.325
	33.4 ± 21.1	30.7 ± 15.7	
Estradiol (pg/mL)	212.9 [140.6]	210.2 [91.9]	0.407
	233.5 ± 118.9	214.6 ± 71.4	
Total Cholesterol (mg/dL)	169.0 [52.5]	165.0 [32.0]	0.020
	168.8 ± 26.3	162.5 ± 22.2	

LDL (mg/dL)	93.0 [45.0]	93.0 [37.5]	0.055
	101.9 ± 23.8	96.2 ± 21.5	
HDL (mg/dL)	49.0 [18.5]	51.0 [15.0]	0.462
	53.8 ± 18.3	52.8 ± 15.3	
Triglycerides (mg/dL)	65.0 [39.0]	53.0 [58.5]	0.887
	64.8 ± 24.0	67.6 ± 36.9	

803 Data shown as median [interquartile range] and mean ± SD. P values obtained via Wilcoxon
804 signed rank test. *Data available in 16 women. † Android (% fat) represents the %total fat within
805 the android (central) region, as opposed to the gynoid (hip and thigh) region.

806





Outpatient Day 10 x 4

Study Drug	Feeling	100 mg	Various
100 mg qd	various	100 mg	various
100 mg qd	various	100 mg	270 min

Inpatient Visit Day 10 x 4

